Clinical trial · Interventional
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer
NCT03193567CI-TRIAL-00082688HEARTrecruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HEKT cell | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HEKT cell
- description
- Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
- interventionNames
- Biological: HEKT cell
Primary outcomes (1)
- measure
- safety：safety index of blood, heart, lung, kidney and brain function damaged mainly during the treatment
- timeFrame
- 2 years
- description
- Occurrence of study related adverse events as assessed by CTCAE v4.0
Secondary outcomes (1)
- measure
- efficacy: complete response; partial response; stable disease; progression disease; progression free survival.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female patients' age from 18 years to 70 years. * Patients who have a life expectancy of at least 3 months. * pathologically confirmed non-small cell lung cancer. * failed in previous standard chemotherapy and targeted therapy. * Karnofsky performance status 0-1. * adequate organ functions. Exclusion Criteria: * Pregnant and lactating women. * Patients with T cell lymphoma, syphilis, AIDS or combination * Patients with highly allergic or have a history of severe allergies * Patients with severe hepatic or renal dysfunction * Patients with severe autoimmune disease or who is being treated with immunosuppressive agents * Patients with severe infection not controlled or High fever * Patients with organ transplantation or waiting for organ transplantation. * Patients with brain metastasis * Patients with severe coagulopathy (e.g. hemophilia) * Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.
References
Publications (0)
Data not yet available
No reference posted for this study.